Patient name,Patient age,Diagnosis type,Cancer type,Clinical trial open for enrollment,Country,County
George Anderson,15,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Waterford
Bob Brown,13,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Dublin
Charlie Anderson,17,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Donegal
Ethan Anderson,11,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Offaly
Charlie Clark,14,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Waterford
George Martin,9,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Hannah Brown,17,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Westmeath
Diana Martin,7,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Wexford
Alice Brown,7,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Monaghan
Fiona Clark,11,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Fiona Smith,8,newly_diagnosed,breast,No open trials,Portugal,
Hannah Brown,8,newly_diagnosed,breast,No open trials,Austria,
Ethan Johnson,8,relapsed,breast,No open trials,Belgium,
Charlie Lee,14,newly_diagnosed,breast,No open trials,Denmark,
Alice Clark,14,relapsed,breast,No open trials,Netherlands,
Bob Taylor,17,relapsed,breast,No open trials,Slovenia,
Hannah Taylor,9,relapsed,breast,No open trials,Germany,
Ethan Taylor,17,relapsed,breast,No open trials,Denmark,
Diana Smith,11,relapsed,breast,No open trials,Malta,
Bob Martin,9,newly_diagnosed,breast,No open trials,Czech Republic,
Fiona Lee,13,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Charlie Taylor,10,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Meath
Charlie Martin,16,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Dublin
Diana Anderson,17,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kerry
Diana Anderson,11,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Waterford
Charlie Smith,12,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Louth
Alice Martin,7,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Longford
Diana Brown,13,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Westmeath
Diana Taylor,17,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Wexford
Bob Anderson,8,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cork
Ethan Anderson,12,relapsed,lung,No open trials,Belgium,
Bob Johnson,15,relapsed,lung,No open trials,Czech Republic,
Diana Johnson,17,relapsed,lung,No open trials,Italy,
Charlie Clark,14,newly_diagnosed,lung,"Establishment of a Tumor Bank for Blood Samples; Establishment of a Tumor Bank for Tissue Samples; A Long-term Extension Study of PCI-32765 (Ibrutinib); Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients; Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer; Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone; A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors; ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation; Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study; Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer; A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab; A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors; Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations; A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer; START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer; A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers; A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1); ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors; A Study of TAS3351 in NSCLC Patients With EGFRmt; Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan; DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers; Predicting Lung Cancer-Associated Cachexia With PET Imaging; Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE); A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.; REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors); A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer; Lung cAncer Robotic Comparative Study; First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations; A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002); PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC; A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer; Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC); A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib; Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment; PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.; A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004); Exercise in Patients With Advanced Non-small Cell Lung Cancer; Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab); A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC); NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations; A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%; A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features; A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).; Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR); Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity; A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4); Radiation-induced Toxicity of the Heart",Germany,
Fiona Johnson,7,relapsed,lung,No open trials,Greece,
George Clark,16,newly_diagnosed,lung,No open trials,Lithuania,
Alice Martin,15,relapsed,lung,No open trials,Czech Republic,
Charlie Anderson,11,relapsed,lung,No open trials,Malta,
Ethan Taylor,15,relapsed,lung,No open trials,Slovakia,
Diana Martin,17,newly_diagnosed,lung,No open trials,Luxembourg,
Hannah Clark,7,newly_diagnosed,CLL,No open trials,Ireland,Sligo
Ethan Clark,8,relapsed,CLL,No open trials,Ireland,Donegal
Hannah Anderson,9,newly_diagnosed,CLL,No open trials,Ireland,Meath
Alice Taylor,16,newly_diagnosed,CLL,No open trials,Ireland,Sligo
George Martin,15,newly_diagnosed,CLL,No open trials,Ireland,Carlow
Alice Martin,17,relapsed,CLL,No open trials,Ireland,Kildare
Bob Anderson,8,newly_diagnosed,CLL,No open trials,Ireland,Galway
Charlie Johnson,7,relapsed,CLL,No open trials,Ireland,Louth
George Martin,13,newly_diagnosed,CLL,No open trials,Ireland,Wexford
Charlie Lee,15,newly_diagnosed,CLL,No open trials,Ireland,Louth
Diana Brown,8,newly_diagnosed,CLL,No open trials,Hungary,
George Lee,15,relapsed,CLL,No open trials,Cyprus,
Charlie Lee,10,relapsed,CLL,No open trials,Germany,
Hannah Anderson,7,relapsed,CLL,No open trials,Cyprus,
George Johnson,16,newly_diagnosed,CLL,No open trials,Greece,
Charlie Anderson,10,relapsed,CLL,No open trials,Slovenia,
Diana Smith,11,relapsed,CLL,No open trials,Slovenia,
Bob Smith,7,newly_diagnosed,CLL,No open trials,Portugal,
Diana Brown,7,newly_diagnosed,CLL,No open trials,Greece,
Bob Martin,10,newly_diagnosed,CLL,No open trials,Latvia,
Diana Smith,16,newly_diagnosed,myeloma,No open trials,Ireland,Sligo
George Anderson,10,newly_diagnosed,myeloma,No open trials,Ireland,Limerick
Alice Lee,15,relapsed,myeloma,No open trials,Ireland,Mayo
Charlie Clark,12,relapsed,myeloma,No open trials,Ireland,Mayo
Hannah Brown,17,newly_diagnosed,myeloma,No open trials,Ireland,Tipperary
Fiona Lee,7,relapsed,myeloma,No open trials,Ireland,Dublin
Hannah Lee,11,newly_diagnosed,myeloma,No open trials,Ireland,Monaghan
Ethan Anderson,8,newly_diagnosed,myeloma,No open trials,Ireland,Kilkenny
Fiona Brown,14,newly_diagnosed,myeloma,No open trials,Ireland,Cavan
George Lee,7,newly_diagnosed,myeloma,No open trials,Ireland,Kilkenny
Ethan Anderson,13,relapsed,myeloma,No open trials,Greece,
Fiona Clark,12,relapsed,myeloma,No open trials,Austria,
Ethan Brown,16,newly_diagnosed,myeloma,No open trials,Bulgaria,
Ethan Taylor,7,newly_diagnosed,myeloma,No open trials,Greece,
Hannah Martin,17,relapsed,myeloma,No open trials,Estonia,
Fiona Taylor,11,relapsed,myeloma,No open trials,Slovakia,
Fiona Smith,8,relapsed,myeloma,No open trials,Croatia,
Hannah Brown,17,relapsed,myeloma,No open trials,Germany,
Fiona Anderson,12,relapsed,myeloma,No open trials,Finland,
Charlie Johnson,17,relapsed,myeloma,No open trials,Belgium,
Charlie Taylor,15,newly_diagnosed,prostate,No open trials,Ireland,Galway
Charlie Clark,16,newly_diagnosed,prostate,No open trials,Ireland,Carlow
Hannah Taylor,17,relapsed,prostate,No open trials,Ireland,Carlow
Ethan Lee,15,newly_diagnosed,prostate,No open trials,Ireland,Leitrim
Diana Brown,17,newly_diagnosed,prostate,No open trials,Ireland,Sligo
Charlie Clark,13,relapsed,prostate,No open trials,Ireland,Monaghan
Ethan Smith,17,newly_diagnosed,prostate,No open trials,Ireland,Longford
Ethan Martin,14,newly_diagnosed,prostate,No open trials,Ireland,Kildare
Ethan Clark,15,relapsed,prostate,No open trials,Ireland,Waterford
George Smith,8,relapsed,prostate,No open trials,Ireland,Cavan
Bob Smith,10,newly_diagnosed,prostate,No open trials,Latvia,
Charlie Smith,17,newly_diagnosed,prostate,No open trials,Greece,
George Clark,7,relapsed,prostate,No open trials,Luxembourg,
Charlie Clark,7,relapsed,prostate,No open trials,Luxembourg,
Hannah Smith,16,newly_diagnosed,prostate,No open trials,Malta,
Bob Lee,13,relapsed,prostate,No open trials,Bulgaria,
Charlie Johnson,8,relapsed,prostate,No open trials,Romania,
George Martin,16,newly_diagnosed,prostate,No open trials,Latvia,
Alice Johnson,14,newly_diagnosed,prostate,No open trials,Spain,
George Martin,16,relapsed,prostate,No open trials,Belgium,
Diana Clark,24,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kildare
Charlie Smith,23,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Bob Clark,28,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Laois
Bob Brown,26,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Charlie Brown,25,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Waterford
Hannah Clark,21,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kildare
Diana Smith,20,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Longford
Diana Johnson,20,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Tipperary
Ethan Anderson,21,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kildare
Alice Lee,26,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Westmeath
Hannah Anderson,24,newly_diagnosed,breast,No open trials,Latvia,
Diana Smith,21,newly_diagnosed,breast,No open trials,Portugal,
George Martin,28,newly_diagnosed,breast,No open trials,Sweden,
George Smith,20,newly_diagnosed,breast,No open trials,Portugal,
Alice Johnson,20,relapsed,breast,No open trials,Bulgaria,
Hannah Clark,22,relapsed,breast,No open trials,Cyprus,
Hannah Brown,23,relapsed,breast,No open trials,Spain,
Fiona Taylor,20,newly_diagnosed,breast,No open trials,Italy,
George Clark,24,relapsed,breast,No open trials,Luxembourg,
Fiona Smith,19,relapsed,breast,No open trials,Finland,
Diana Lee,27,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Clare
Fiona Taylor,21,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Westmeath
Ethan Johnson,21,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Wicklow
Ethan Smith,28,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cavan
Charlie Clark,19,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Longford
George Martin,21,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kerry
Bob Smith,22,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Donegal
Bob Anderson,27,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Waterford
Ethan Johnson,26,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Monaghan
Hannah Lee,26,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Tipperary
Ethan Anderson,23,newly_diagnosed,lung,"Establishment of a Tumor Bank for Blood Samples; Establishment of a Tumor Bank for Tissue Samples; A Long-term Extension Study of PCI-32765 (Ibrutinib); Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients; Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer; Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone; A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors; ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation; Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study; Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer; A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab; A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors; Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations; A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer; START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer; A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers; A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1); ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors; A Study of TAS3351 in NSCLC Patients With EGFRmt; Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan; DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers; Predicting Lung Cancer-Associated Cachexia With PET Imaging; Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE); A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.; REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors); A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer; Lung cAncer Robotic Comparative Study; First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations; A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002); PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC; A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer; Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC); A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib; Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment; PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.; A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004); Exercise in Patients With Advanced Non-small Cell Lung Cancer; Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab); A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC); NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations; A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%; A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features; A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).; Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR); Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity; A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4); Radiation-induced Toxicity of the Heart",Germany,
George Johnson,23,relapsed,lung,No open trials,Sweden,
Hannah Johnson,24,newly_diagnosed,lung,No open trials,Slovakia,
Alice Taylor,25,newly_diagnosed,lung,No open trials,Italy,
Diana Clark,19,newly_diagnosed,lung,No open trials,Latvia,
Alice Johnson,18,newly_diagnosed,lung,No open trials,Czech Republic,
Hannah Johnson,23,newly_diagnosed,lung,No open trials,Slovenia,
Diana Anderson,26,newly_diagnosed,lung,No open trials,Sweden,
Bob Clark,23,newly_diagnosed,lung,No open trials,Luxembourg,
George Anderson,26,newly_diagnosed,lung,No open trials,Portugal,
Alice Anderson,22,newly_diagnosed,CLL,No open trials,Ireland,Cavan
George Clark,18,relapsed,CLL,No open trials,Ireland,Kildare
Bob Taylor,26,newly_diagnosed,CLL,No open trials,Ireland,Wexford
George Lee,23,relapsed,CLL,No open trials,Ireland,Kilkenny
Hannah Smith,26,relapsed,CLL,No open trials,Ireland,Westmeath
Charlie Johnson,19,newly_diagnosed,CLL,No open trials,Ireland,Kilkenny
Hannah Smith,18,relapsed,CLL,No open trials,Ireland,Waterford
Charlie Martin,24,newly_diagnosed,CLL,No open trials,Ireland,Leitrim
Alice Martin,19,relapsed,CLL,No open trials,Ireland,Cavan
Bob Brown,19,newly_diagnosed,CLL,No open trials,Ireland,Clare
Ethan Clark,19,relapsed,CLL,No open trials,Slovakia,
Charlie Smith,22,relapsed,CLL,No open trials,France,
Alice Anderson,27,newly_diagnosed,CLL,No open trials,Luxembourg,
Hannah Anderson,23,newly_diagnosed,CLL,No open trials,Bulgaria,
Bob Lee,28,newly_diagnosed,CLL,No open trials,Germany,
Fiona Brown,27,newly_diagnosed,CLL,No open trials,Czech Republic,
Hannah Johnson,23,relapsed,CLL,No open trials,Finland,
Fiona Brown,22,newly_diagnosed,CLL,No open trials,Malta,
Ethan Lee,18,relapsed,CLL,No open trials,Latvia,
Charlie Martin,20,newly_diagnosed,CLL,No open trials,Lithuania,
George Clark,21,newly_diagnosed,myeloma,No open trials,Ireland,Monaghan
Fiona Brown,22,relapsed,myeloma,No open trials,Ireland,Wicklow
Bob Martin,23,relapsed,myeloma,No open trials,Ireland,Cavan
Fiona Clark,24,relapsed,myeloma,No open trials,Ireland,Wexford
Bob Anderson,25,relapsed,myeloma,No open trials,Ireland,Wexford
Charlie Smith,18,relapsed,myeloma,No open trials,Ireland,Louth
Ethan Taylor,21,relapsed,myeloma,No open trials,Ireland,Kildare
Hannah Martin,20,newly_diagnosed,myeloma,No open trials,Ireland,Longford
Bob Anderson,20,newly_diagnosed,myeloma,No open trials,Ireland,Wexford
Ethan Brown,26,newly_diagnosed,myeloma,No open trials,Ireland,Kilkenny
Alice Johnson,18,relapsed,myeloma,No open trials,Luxembourg,
Charlie Johnson,19,relapsed,myeloma,No open trials,Luxembourg,
Ethan Johnson,23,relapsed,myeloma,No open trials,Austria,
Charlie Martin,18,newly_diagnosed,myeloma,No open trials,Slovakia,
Ethan Lee,19,relapsed,myeloma,No open trials,Czech Republic,
Fiona Brown,20,newly_diagnosed,myeloma,No open trials,Greece,
George Johnson,26,newly_diagnosed,myeloma,No open trials,Luxembourg,
Hannah Taylor,27,newly_diagnosed,myeloma,No open trials,Cyprus,
Bob Brown,26,relapsed,myeloma,No open trials,France,
Charlie Martin,18,newly_diagnosed,myeloma,No open trials,Slovakia,
George Taylor,27,relapsed,prostate,No open trials,Ireland,Roscommon
Alice Johnson,25,newly_diagnosed,prostate,No open trials,Ireland,Leitrim
Alice Clark,26,relapsed,prostate,No open trials,Ireland,Monaghan
Ethan Johnson,22,newly_diagnosed,prostate,No open trials,Ireland,Kerry
Bob Johnson,20,newly_diagnosed,prostate,No open trials,Ireland,Longford
Hannah Clark,26,relapsed,prostate,No open trials,Ireland,Waterford
Fiona Brown,18,newly_diagnosed,prostate,No open trials,Ireland,Tipperary
Hannah Anderson,18,relapsed,prostate,No open trials,Ireland,Donegal
Diana Lee,27,newly_diagnosed,prostate,No open trials,Ireland,Tipperary
Diana Clark,24,relapsed,prostate,No open trials,Ireland,Wicklow
Bob Lee,26,newly_diagnosed,prostate,No open trials,Portugal,
Hannah Anderson,18,newly_diagnosed,prostate,No open trials,Lithuania,
Alice Lee,25,newly_diagnosed,prostate,No open trials,Luxembourg,
Ethan Clark,18,newly_diagnosed,prostate,No open trials,Germany,
Bob Anderson,26,relapsed,prostate,No open trials,Italy,
Ethan Brown,19,relapsed,prostate,No open trials,Bulgaria,
Fiona Lee,28,newly_diagnosed,prostate,No open trials,Belgium,
Charlie Johnson,19,newly_diagnosed,prostate,No open trials,Cyprus,
Ethan Taylor,27,newly_diagnosed,prostate,No open trials,Poland,
Alice Anderson,19,newly_diagnosed,prostate,No open trials,Croatia,
Diana Lee,30,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Charlie Martin,38,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Offaly
Ethan Clark,37,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Dublin
Bob Lee,33,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Carlow
Ethan Anderson,32,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Laois
Diana Clark,34,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Tipperary
Fiona Lee,29,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Westmeath
Diana Johnson,38,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Limerick
Hannah Clark,36,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Waterford
Ethan Johnson,33,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Galway
Ethan Johnson,37,relapsed,breast,No open trials,Malta,
George Lee,36,relapsed,breast,No open trials,Italy,
Diana Clark,35,relapsed,breast,No open trials,Croatia,
Diana Brown,29,relapsed,breast,No open trials,Denmark,
Fiona Clark,37,relapsed,breast,No open trials,Germany,
Diana Martin,37,relapsed,breast,No open trials,Croatia,
Diana Anderson,30,newly_diagnosed,breast,No open trials,Slovakia,
Charlie Clark,38,newly_diagnosed,breast,No open trials,Luxembourg,
Alice Johnson,38,relapsed,breast,No open trials,Luxembourg,
Charlie Taylor,31,newly_diagnosed,breast,No open trials,Austria,
Hannah Brown,37,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Westmeath
George Anderson,32,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Roscommon
George Smith,37,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Galway
Diana Brown,35,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Bob Martin,30,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kerry
George Smith,35,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Monaghan
Charlie Smith,36,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Monaghan
Ethan Brown,34,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Wicklow
Alice Clark,37,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cavan
Ethan Martin,35,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kerry
Bob Taylor,30,newly_diagnosed,lung,No open trials,Belgium,
George Brown,30,newly_diagnosed,lung,No open trials,Belgium,
Charlie Brown,38,newly_diagnosed,lung,No open trials,Estonia,
Alice Smith,31,newly_diagnosed,lung,No open trials,Luxembourg,
Fiona Martin,36,relapsed,lung,No open trials,Spain,
Charlie Smith,30,newly_diagnosed,lung,No open trials,France,
Ethan Johnson,35,relapsed,lung,A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21); A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4),Croatia,
Hannah Brown,38,relapsed,lung,No open trials,Spain,
George Taylor,31,newly_diagnosed,lung,No open trials,Cyprus,
Ethan Johnson,37,relapsed,lung,No open trials,Netherlands,
Ethan Taylor,38,newly_diagnosed,CLL,No open trials,Ireland,Wexford
Fiona Brown,32,relapsed,CLL,No open trials,Ireland,Sligo
Ethan Martin,29,newly_diagnosed,CLL,No open trials,Ireland,Carlow
Ethan Smith,30,relapsed,CLL,No open trials,Ireland,Cavan
Ethan Lee,37,newly_diagnosed,CLL,No open trials,Ireland,Wexford
Charlie Smith,31,newly_diagnosed,CLL,No open trials,Ireland,Limerick
Diana Johnson,37,newly_diagnosed,CLL,No open trials,Ireland,Clare
Charlie Johnson,37,newly_diagnosed,CLL,No open trials,Ireland,Waterford
Alice Smith,35,relapsed,CLL,No open trials,Ireland,Kildare
Hannah Smith,29,newly_diagnosed,CLL,No open trials,Ireland,Leitrim
Bob Martin,30,relapsed,CLL,No open trials,France,
Charlie Smith,36,newly_diagnosed,CLL,No open trials,Latvia,
Fiona Smith,35,newly_diagnosed,CLL,No open trials,Portugal,
Fiona Anderson,38,newly_diagnosed,CLL,No open trials,France,
Ethan Lee,38,newly_diagnosed,CLL,No open trials,Lithuania,
Charlie Martin,29,relapsed,CLL,No open trials,Estonia,
George Brown,32,newly_diagnosed,CLL,No open trials,Poland,
Ethan Anderson,32,newly_diagnosed,CLL,No open trials,Slovenia,
Ethan Johnson,33,relapsed,CLL,No open trials,Sweden,
Fiona Smith,33,relapsed,CLL,No open trials,Latvia,
Charlie Brown,37,newly_diagnosed,myeloma,No open trials,Ireland,Kilkenny
George Lee,35,newly_diagnosed,myeloma,No open trials,Ireland,Tipperary
Diana Smith,38,newly_diagnosed,myeloma,No open trials,Ireland,Cork
Ethan Johnson,29,newly_diagnosed,myeloma,No open trials,Ireland,Limerick
George Lee,31,newly_diagnosed,myeloma,No open trials,Ireland,Wicklow
Diana Brown,33,newly_diagnosed,myeloma,No open trials,Ireland,Carlow
Bob Johnson,33,newly_diagnosed,myeloma,No open trials,Ireland,Kerry
Fiona Taylor,30,relapsed,myeloma,No open trials,Ireland,Galway
Ethan Clark,32,newly_diagnosed,myeloma,No open trials,Ireland,Leitrim
Bob Anderson,31,newly_diagnosed,myeloma,No open trials,Ireland,Sligo
Alice Johnson,34,newly_diagnosed,myeloma,No open trials,Hungary,
Diana Clark,37,newly_diagnosed,myeloma,No open trials,Spain,
Bob Anderson,38,relapsed,myeloma,No open trials,Greece,
Fiona Anderson,31,relapsed,myeloma,No open trials,Luxembourg,
Hannah Martin,36,newly_diagnosed,myeloma,No open trials,Hungary,
George Brown,36,relapsed,myeloma,No open trials,Slovenia,
Diana Smith,36,relapsed,myeloma,No open trials,Netherlands,
Charlie Martin,37,newly_diagnosed,myeloma,No open trials,Bulgaria,
Charlie Anderson,33,relapsed,myeloma,No open trials,Romania,
Alice Brown,30,relapsed,myeloma,No open trials,Hungary,
Charlie Anderson,35,newly_diagnosed,prostate,No open trials,Ireland,Longford
Ethan Martin,32,relapsed,prostate,No open trials,Ireland,Galway
Alice Brown,32,newly_diagnosed,prostate,No open trials,Ireland,Kildare
Diana Taylor,38,newly_diagnosed,prostate,No open trials,Ireland,Waterford
Alice Anderson,33,newly_diagnosed,prostate,No open trials,Ireland,Limerick
Alice Taylor,30,newly_diagnosed,prostate,No open trials,Ireland,Clare
Fiona Anderson,35,newly_diagnosed,prostate,No open trials,Ireland,Dublin
George Clark,29,newly_diagnosed,prostate,No open trials,Ireland,Kerry
Ethan Taylor,36,newly_diagnosed,prostate,No open trials,Ireland,Longford
Hannah Anderson,29,newly_diagnosed,prostate,No open trials,Ireland,Carlow
George Anderson,34,relapsed,prostate,No open trials,Romania,
Bob Lee,38,newly_diagnosed,prostate,No open trials,Belgium,
Hannah Taylor,30,newly_diagnosed,prostate,No open trials,Sweden,
Alice Clark,30,relapsed,prostate,No open trials,Romania,
George Anderson,38,newly_diagnosed,prostate,No open trials,Sweden,
Diana Martin,32,relapsed,prostate,No open trials,Germany,
Ethan Anderson,33,relapsed,prostate,No open trials,Estonia,
Charlie Anderson,37,newly_diagnosed,prostate,No open trials,Bulgaria,
Hannah Smith,37,relapsed,prostate,No open trials,Finland,
Alice Taylor,36,newly_diagnosed,prostate,No open trials,Luxembourg,
Diana Brown,48,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Cavan
Fiona Clark,42,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Meath
Fiona Clark,44,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Clare
Bob Martin,43,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
George Smith,47,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kilkenny
Alice Anderson,48,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Meath
Alice Lee,45,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Dublin
Diana Brown,47,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Carlow
Ethan Smith,39,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Cork
Diana Lee,46,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Mayo
Charlie Clark,41,newly_diagnosed,breast,No open trials,Bulgaria,
Fiona Brown,48,newly_diagnosed,breast,No open trials,Sweden,
Ethan Taylor,47,newly_diagnosed,breast,No open trials,Germany,
Alice Lee,48,relapsed,breast,No open trials,Lithuania,
Fiona Taylor,46,newly_diagnosed,breast,No open trials,Finland,
Charlie Clark,47,newly_diagnosed,breast,No open trials,Czech Republic,
Diana Martin,44,newly_diagnosed,breast,No open trials,Denmark,
Fiona Lee,40,relapsed,breast,No open trials,Cyprus,
Alice Brown,44,relapsed,breast,No open trials,Bulgaria,
Fiona Martin,40,relapsed,breast,No open trials,Denmark,
Charlie Johnson,39,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Bob Taylor,43,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Longford
Fiona Brown,39,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cavan
Diana Smith,46,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Wicklow
Fiona Johnson,43,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Westmeath
Charlie Lee,47,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Mayo
Charlie Anderson,47,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Wexford
Charlie Anderson,44,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cavan
Alice Clark,44,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Louth
Hannah Taylor,41,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Louth
Charlie Smith,45,newly_diagnosed,lung,No open trials,Denmark,
Charlie Brown,40,relapsed,lung,No open trials,Malta,
Charlie Anderson,43,relapsed,lung,"Establishment of a Tumor Bank for Blood Samples; Establishment of a Tumor Bank for Tissue Samples; A Long-term Extension Study of PCI-32765 (Ibrutinib); Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients; Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer; Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone; A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors; ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation; Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study; Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer; A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab; A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors; Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations; A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer; START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer; A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers; A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1); ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors; A Study of TAS3351 in NSCLC Patients With EGFRmt; Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan; DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers; Predicting Lung Cancer-Associated Cachexia With PET Imaging; Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE); A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.; REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors); A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer; Lung cAncer Robotic Comparative Study; First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations; A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002); PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC; A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer; Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC); A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib; Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment; PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.; A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004); Exercise in Patients With Advanced Non-small Cell Lung Cancer; Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab); A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC); NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations; A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%; A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features; A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).; Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR); Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity; A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4); Radiation-induced Toxicity of the Heart",Germany,
Ethan Lee,48,newly_diagnosed,lung,No open trials,Bulgaria,
George Martin,47,relapsed,lung,No open trials,France,
Alice Brown,42,newly_diagnosed,lung,No open trials,Portugal,
Alice Johnson,48,relapsed,lung,No open trials,Austria,
Charlie Brown,45,newly_diagnosed,lung,No open trials,Latvia,
Charlie Smith,43,relapsed,lung,No open trials,Sweden,
Fiona Johnson,48,relapsed,lung,"Establishment of a Tumor Bank for Blood Samples; Establishment of a Tumor Bank for Tissue Samples; A Long-term Extension Study of PCI-32765 (Ibrutinib); Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients; Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer; Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone; A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors; ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation; Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study; Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer; A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab; A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors; Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations; A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer; START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer; A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers; A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1); ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors; A Study of TAS3351 in NSCLC Patients With EGFRmt; Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan; DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers; Predicting Lung Cancer-Associated Cachexia With PET Imaging; Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE); A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.; REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors); A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer; Lung cAncer Robotic Comparative Study; First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations; A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002); PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC; A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer; Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC); A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib; Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment; PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.; A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004); Exercise in Patients With Advanced Non-small Cell Lung Cancer; Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab); A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC); NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations; A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%; A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features; A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).; Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR); Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity; A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4); Radiation-induced Toxicity of the Heart",Germany,
George Lee,46,relapsed,CLL,No open trials,Ireland,Laois
Diana Johnson,44,newly_diagnosed,CLL,No open trials,Ireland,Laois
George Anderson,40,relapsed,CLL,No open trials,Ireland,Clare
Fiona Smith,41,relapsed,CLL,No open trials,Ireland,Laois
George Taylor,43,relapsed,CLL,No open trials,Ireland,Mayo
Ethan Clark,46,relapsed,CLL,No open trials,Ireland,Mayo
Ethan Martin,43,newly_diagnosed,CLL,No open trials,Ireland,Longford
Charlie Brown,44,newly_diagnosed,CLL,No open trials,Ireland,Tipperary
Diana Martin,45,relapsed,CLL,No open trials,Ireland,Tipperary
George Brown,44,relapsed,CLL,No open trials,Ireland,Leitrim
Bob Martin,44,newly_diagnosed,CLL,No open trials,Portugal,
George Johnson,48,newly_diagnosed,CLL,No open trials,Greece,
Alice Johnson,43,relapsed,CLL,No open trials,Czech Republic,
Bob Lee,44,newly_diagnosed,CLL,No open trials,Poland,
Hannah Clark,39,relapsed,CLL,No open trials,Italy,
Alice Anderson,44,relapsed,CLL,No open trials,Latvia,
Fiona Anderson,46,relapsed,CLL,No open trials,France,
George Brown,47,relapsed,CLL,No open trials,Slovakia,
George Smith,45,relapsed,CLL,No open trials,France,
Bob Martin,40,newly_diagnosed,CLL,No open trials,Latvia,
Bob Clark,44,newly_diagnosed,myeloma,No open trials,Ireland,Kildare
Fiona Smith,47,relapsed,myeloma,No open trials,Ireland,Limerick
Fiona Lee,40,newly_diagnosed,myeloma,No open trials,Ireland,Clare
Ethan Johnson,40,relapsed,myeloma,No open trials,Ireland,Galway
Alice Brown,48,relapsed,myeloma,No open trials,Ireland,Carlow
Alice Taylor,44,relapsed,myeloma,No open trials,Ireland,Wexford
Bob Johnson,41,relapsed,myeloma,No open trials,Ireland,Galway
Ethan Smith,42,newly_diagnosed,myeloma,No open trials,Ireland,Donegal
Fiona Johnson,48,relapsed,myeloma,No open trials,Ireland,Galway
Diana Smith,42,relapsed,myeloma,No open trials,Ireland,Cork
Ethan Taylor,41,relapsed,myeloma,No open trials,Poland,
Charlie Brown,43,newly_diagnosed,myeloma,No open trials,Denmark,
Alice Taylor,42,newly_diagnosed,myeloma,No open trials,Poland,
Fiona Clark,48,newly_diagnosed,myeloma,No open trials,Italy,
Bob Brown,41,newly_diagnosed,myeloma,No open trials,Austria,
Diana Martin,47,newly_diagnosed,myeloma,No open trials,Slovakia,
Diana Brown,39,newly_diagnosed,myeloma,No open trials,Romania,
Alice Martin,45,relapsed,myeloma,No open trials,Denmark,
Fiona Brown,48,newly_diagnosed,myeloma,No open trials,Greece,
Bob Taylor,43,newly_diagnosed,myeloma,No open trials,Finland,
Fiona Clark,45,relapsed,prostate,No open trials,Ireland,Wicklow
Fiona Taylor,40,relapsed,prostate,No open trials,Ireland,Cavan
Bob Brown,47,relapsed,prostate,No open trials,Ireland,Dublin
Charlie Clark,44,newly_diagnosed,prostate,No open trials,Ireland,Monaghan
Alice Smith,46,relapsed,prostate,No open trials,Ireland,Wicklow
Alice Brown,40,relapsed,prostate,No open trials,Ireland,Cavan
George Clark,41,relapsed,prostate,No open trials,Ireland,Roscommon
Diana Anderson,40,newly_diagnosed,prostate,No open trials,Ireland,Roscommon
Diana Smith,41,relapsed,prostate,No open trials,Ireland,Roscommon
Charlie Martin,47,relapsed,prostate,No open trials,Ireland,Monaghan
George Martin,48,relapsed,prostate,No open trials,Sweden,
Bob Clark,44,newly_diagnosed,prostate,No open trials,Slovenia,
Fiona Clark,43,relapsed,prostate,No open trials,Bulgaria,
Fiona Lee,44,newly_diagnosed,prostate,No open trials,Germany,
Fiona Johnson,40,relapsed,prostate,No open trials,Malta,
Charlie Johnson,39,relapsed,prostate,No open trials,Austria,
Ethan Brown,41,newly_diagnosed,prostate,No open trials,Luxembourg,
Ethan Anderson,40,relapsed,prostate,No open trials,Cyprus,
Charlie Lee,43,relapsed,prostate,No open trials,Bulgaria,
Charlie Brown,41,relapsed,prostate,No open trials,Portugal,
Fiona Smith,54,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Longford
George Johnson,57,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Offaly
Hannah Anderson,54,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Wexford
Bob Clark,54,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Dublin
Diana Brown,49,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Donegal
Diana Smith,55,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Longford
Bob Johnson,58,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Leitrim
Diana Taylor,52,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Diana Smith,50,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Waterford
Charlie Smith,58,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Fiona Johnson,54,newly_diagnosed,breast,No open trials,Portugal,
Fiona Johnson,49,newly_diagnosed,breast,No open trials,Cyprus,
Hannah Lee,56,newly_diagnosed,breast,No open trials,Belgium,
Fiona Brown,52,relapsed,breast,No open trials,Romania,
Bob Lee,55,relapsed,breast,No open trials,Poland,
Hannah Brown,53,relapsed,breast,No open trials,Luxembourg,
Diana Clark,49,relapsed,breast,No open trials,Greece,
George Lee,50,relapsed,breast,No open trials,Finland,
George Clark,51,relapsed,breast,No open trials,Lithuania,
Hannah Smith,57,relapsed,breast,No open trials,Cyprus,
George Brown,58,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Sligo
Ethan Taylor,56,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Laois
George Anderson,55,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Clare
George Lee,54,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Westmeath
Ethan Lee,54,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cork
Alice Johnson,52,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Sligo
Charlie Taylor,51,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Galway
George Johnson,52,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Mayo
Fiona Johnson,58,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Dublin
Diana Anderson,56,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Charlie Anderson,52,relapsed,lung,No open trials,Belgium,
Alice Lee,49,newly_diagnosed,lung,No open trials,Finland,
George Martin,54,newly_diagnosed,lung,No open trials,Bulgaria,
George Taylor,52,relapsed,lung,"Establishment of a Tumor Bank for Blood Samples; Establishment of a Tumor Bank for Tissue Samples; A Long-term Extension Study of PCI-32765 (Ibrutinib); Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients; Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer; Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone; A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors; ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation; Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study; Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer; A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab; A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors; Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations; A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer; START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer; A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers; A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1); ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors; A Study of TAS3351 in NSCLC Patients With EGFRmt; Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan; DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers; Predicting Lung Cancer-Associated Cachexia With PET Imaging; Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE); A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.; REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors); A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer; Lung cAncer Robotic Comparative Study; First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations; A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002); PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC; A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer; Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC); A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib; Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment; PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.; A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004); Exercise in Patients With Advanced Non-small Cell Lung Cancer; Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab); A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC); NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations; A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%; A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features; A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).; Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR); Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity; A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4); Radiation-induced Toxicity of the Heart",Germany,
Bob Martin,50,newly_diagnosed,lung,No open trials,Hungary,
Bob Clark,54,relapsed,lung,No open trials,Luxembourg,
Alice Brown,56,relapsed,lung,No open trials,Belgium,
Diana Brown,51,relapsed,lung,A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21); A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4),Croatia,
George Clark,57,relapsed,lung,No open trials,Estonia,
Fiona Clark,50,relapsed,lung,No open trials,Czech Republic,
Charlie Lee,57,newly_diagnosed,CLL,No open trials,Ireland,Westmeath
Charlie Lee,54,newly_diagnosed,CLL,No open trials,Ireland,Waterford
Bob Taylor,55,newly_diagnosed,CLL,No open trials,Ireland,Roscommon
Bob Smith,50,newly_diagnosed,CLL,No open trials,Ireland,Cavan
Charlie Anderson,56,newly_diagnosed,CLL,No open trials,Ireland,Galway
George Taylor,55,newly_diagnosed,CLL,No open trials,Ireland,Leitrim
Charlie Clark,52,newly_diagnosed,CLL,No open trials,Ireland,Wicklow
Hannah Anderson,50,newly_diagnosed,CLL,No open trials,Ireland,Offaly
Ethan Taylor,57,newly_diagnosed,CLL,No open trials,Ireland,Offaly
George Anderson,52,relapsed,CLL,No open trials,Ireland,Cavan
Hannah Lee,52,relapsed,CLL,No open trials,Estonia,
Ethan Martin,51,newly_diagnosed,CLL,No open trials,Lithuania,
Ethan Lee,50,newly_diagnosed,CLL,No open trials,Cyprus,
Hannah Johnson,58,relapsed,CLL,No open trials,Spain,
Diana Brown,54,newly_diagnosed,CLL,No open trials,Poland,
Bob Taylor,55,relapsed,CLL,No open trials,Hungary,
Diana Lee,55,newly_diagnosed,CLL,No open trials,Luxembourg,
Diana Johnson,53,relapsed,CLL,No open trials,Czech Republic,
Bob Clark,50,relapsed,CLL,No open trials,Slovakia,
Charlie Brown,51,newly_diagnosed,CLL,No open trials,Sweden,
Hannah Brown,54,relapsed,myeloma,No open trials,Ireland,Clare
Fiona Taylor,56,newly_diagnosed,myeloma,No open trials,Ireland,Waterford
Diana Anderson,50,relapsed,myeloma,No open trials,Ireland,Mayo
Ethan Smith,53,newly_diagnosed,myeloma,No open trials,Ireland,Louth
Alice Johnson,54,newly_diagnosed,myeloma,No open trials,Ireland,Kildare
Hannah Smith,51,relapsed,myeloma,No open trials,Ireland,Clare
Charlie Martin,55,relapsed,myeloma,No open trials,Ireland,Waterford
Ethan Johnson,54,relapsed,myeloma,No open trials,Ireland,Kildare
Fiona Brown,53,relapsed,myeloma,No open trials,Ireland,Mayo
Ethan Brown,56,newly_diagnosed,myeloma,No open trials,Ireland,Wicklow
George Anderson,57,relapsed,myeloma,No open trials,Romania,
Charlie Lee,52,relapsed,myeloma,No open trials,Lithuania,
Bob Lee,49,newly_diagnosed,myeloma,No open trials,Latvia,
Ethan Smith,49,relapsed,myeloma,No open trials,Greece,
Charlie Anderson,49,relapsed,myeloma,No open trials,Hungary,
Hannah Johnson,50,relapsed,myeloma,No open trials,Luxembourg,
Hannah Smith,57,newly_diagnosed,myeloma,No open trials,Belgium,
Charlie Brown,52,relapsed,myeloma,No open trials,Poland,
George Anderson,52,relapsed,myeloma,No open trials,Hungary,
Bob Taylor,55,relapsed,myeloma,No open trials,Austria,
Bob Brown,52,relapsed,prostate,No open trials,Ireland,Cavan
Hannah Anderson,55,relapsed,prostate,No open trials,Ireland,Dublin
Fiona Brown,54,relapsed,prostate,No open trials,Ireland,Meath
Bob Taylor,53,relapsed,prostate,No open trials,Ireland,Longford
Charlie Lee,53,newly_diagnosed,prostate,No open trials,Ireland,Limerick
Charlie Smith,58,relapsed,prostate,No open trials,Ireland,Louth
Charlie Taylor,56,relapsed,prostate,No open trials,Ireland,Longford
Ethan Smith,54,newly_diagnosed,prostate,No open trials,Ireland,Wexford
Ethan Lee,54,relapsed,prostate,No open trials,Ireland,Offaly
Fiona Johnson,49,newly_diagnosed,prostate,No open trials,Ireland,Wexford
Ethan Taylor,55,relapsed,prostate,No open trials,Italy,
Fiona Lee,58,relapsed,prostate,No open trials,Bulgaria,
Hannah Smith,55,newly_diagnosed,prostate,No open trials,Slovakia,
Diana Smith,51,relapsed,prostate,No open trials,France,
Hannah Lee,51,relapsed,prostate,No open trials,Portugal,
Hannah Brown,51,newly_diagnosed,prostate,No open trials,Hungary,
Alice Anderson,51,newly_diagnosed,prostate,No open trials,Bulgaria,
Diana Brown,51,newly_diagnosed,prostate,No open trials,Spain,
George Brown,54,relapsed,prostate,No open trials,Netherlands,
Fiona Martin,52,relapsed,prostate,No open trials,Czech Republic,
Hannah Brown,66,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kildare
Diana Martin,65,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Clare
Fiona Martin,67,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Tipperary
Fiona Johnson,66,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Fiona Lee,63,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Monaghan
George Smith,67,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Wicklow
Diana Clark,59,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Meath
George Anderson,68,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Offaly
Fiona Johnson,64,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Carlow
George Johnson,59,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Longford
Hannah Smith,67,relapsed,breast,No open trials,Italy,
Diana Taylor,66,relapsed,breast,No open trials,Romania,
Charlie Smith,62,newly_diagnosed,breast,No open trials,Czech Republic,
George Taylor,65,newly_diagnosed,breast,No open trials,Romania,
George Clark,65,relapsed,breast,No open trials,Poland,
Bob Brown,60,newly_diagnosed,breast,No open trials,Luxembourg,
Ethan Martin,65,newly_diagnosed,breast,No open trials,Sweden,
Ethan Clark,62,newly_diagnosed,breast,No open trials,Czech Republic,
Hannah Smith,67,newly_diagnosed,breast,No open trials,Lithuania,
Fiona Martin,68,relapsed,breast,No open trials,Sweden,
Fiona Smith,67,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Hannah Johnson,66,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Meath
George Clark,63,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Offaly
Charlie Martin,67,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Clare
Diana Taylor,68,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Diana Taylor,63,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Cavan
Alice Anderson,59,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Tipperary
Bob Anderson,65,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Leitrim
Fiona Anderson,68,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kilkenny
Bob Anderson,59,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Tipperary
Alice Lee,68,relapsed,lung,No open trials,Romania,
Ethan Taylor,65,relapsed,lung,No open trials,Denmark,
George Johnson,65,relapsed,lung,No open trials,Latvia,
Hannah Smith,63,relapsed,lung,No open trials,Finland,
Fiona Taylor,65,relapsed,lung,"Establishment of a Tumor Bank for Blood Samples; Establishment of a Tumor Bank for Tissue Samples; A Long-term Extension Study of PCI-32765 (Ibrutinib); Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients; Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer; Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone; A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements; Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7; A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors; ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation; Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study; Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer; A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab; A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors; Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations; A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer; START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer; A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers; A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1); ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors; A Study of TAS3351 in NSCLC Patients With EGFRmt; Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan; DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers; Predicting Lung Cancer-Associated Cachexia With PET Imaging; Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE); A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.; REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors); A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer; Lung cAncer Robotic Comparative Study; First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations; A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002); PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC; A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer; Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC); A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer; Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib; Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment; PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.; A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004); Exercise in Patients With Advanced Non-small Cell Lung Cancer; Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab); A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC); NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations; A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%; A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features; A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).; Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR); Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity; A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4); Radiation-induced Toxicity of the Heart",Germany,
Charlie Smith,67,relapsed,lung,No open trials,Portugal,
Diana Smith,60,newly_diagnosed,lung,No open trials,Denmark,
Bob Lee,60,relapsed,lung,No open trials,Sweden,
George Smith,60,newly_diagnosed,lung,No open trials,Hungary,
Hannah Anderson,61,newly_diagnosed,lung,No open trials,Slovenia,
Bob Clark,60,newly_diagnosed,CLL,No open trials,Ireland,Wicklow
George Anderson,66,relapsed,CLL,No open trials,Ireland,Cork
Diana Brown,63,newly_diagnosed,CLL,No open trials,Ireland,Galway
Charlie Johnson,66,newly_diagnosed,CLL,No open trials,Ireland,Offaly
Charlie Anderson,63,relapsed,CLL,No open trials,Ireland,Kildare
Ethan Johnson,60,relapsed,CLL,No open trials,Ireland,Mayo
Alice Smith,67,relapsed,CLL,No open trials,Ireland,Longford
Alice Anderson,65,newly_diagnosed,CLL,No open trials,Ireland,Wexford
George Anderson,61,relapsed,CLL,No open trials,Ireland,Monaghan
Alice Martin,60,relapsed,CLL,No open trials,Ireland,Wicklow
George Martin,64,relapsed,CLL,No open trials,Bulgaria,
Hannah Clark,59,relapsed,CLL,No open trials,Estonia,
Diana Smith,59,relapsed,CLL,No open trials,Sweden,
Fiona Taylor,68,relapsed,CLL,No open trials,Finland,
George Smith,61,relapsed,CLL,No open trials,Lithuania,
Ethan Smith,65,newly_diagnosed,CLL,No open trials,Spain,
Diana Taylor,59,newly_diagnosed,CLL,No open trials,Luxembourg,
Bob Brown,63,newly_diagnosed,CLL,No open trials,Belgium,
Hannah Anderson,63,relapsed,CLL,No open trials,Croatia,
Bob Brown,59,relapsed,CLL,No open trials,Slovenia,
George Taylor,64,newly_diagnosed,myeloma,No open trials,Ireland,Mayo
Fiona Martin,59,newly_diagnosed,myeloma,No open trials,Ireland,Galway
Fiona Smith,63,newly_diagnosed,myeloma,No open trials,Ireland,Kildare
Fiona Clark,63,newly_diagnosed,myeloma,No open trials,Ireland,Cork
Diana Clark,59,relapsed,myeloma,No open trials,Ireland,Galway
Diana Johnson,59,relapsed,myeloma,No open trials,Ireland,Laois
George Taylor,61,relapsed,myeloma,No open trials,Ireland,Donegal
Fiona Brown,65,newly_diagnosed,myeloma,No open trials,Ireland,Clare
George Clark,63,newly_diagnosed,myeloma,No open trials,Ireland,Wicklow
George Clark,65,relapsed,myeloma,No open trials,Ireland,Monaghan
Fiona Martin,66,relapsed,myeloma,No open trials,Netherlands,
Charlie Martin,66,relapsed,myeloma,No open trials,Hungary,
Diana Anderson,64,newly_diagnosed,myeloma,No open trials,Luxembourg,
Bob Smith,63,newly_diagnosed,myeloma,No open trials,France,
Charlie Smith,66,relapsed,myeloma,No open trials,Cyprus,
Alice Taylor,60,newly_diagnosed,myeloma,No open trials,Spain,
Diana Clark,68,newly_diagnosed,myeloma,No open trials,Spain,
Alice Brown,61,relapsed,myeloma,No open trials,Czech Republic,
Alice Anderson,61,relapsed,myeloma,No open trials,Slovenia,
Hannah Martin,62,newly_diagnosed,myeloma,No open trials,Latvia,
Fiona Brown,59,relapsed,prostate,No open trials,Ireland,Galway
George Taylor,67,relapsed,prostate,No open trials,Ireland,Offaly
George Lee,64,relapsed,prostate,No open trials,Ireland,Laois
George Taylor,64,newly_diagnosed,prostate,No open trials,Ireland,Carlow
Diana Clark,64,relapsed,prostate,No open trials,Ireland,Limerick
Hannah Martin,63,relapsed,prostate,No open trials,Ireland,Clare
Diana Martin,65,relapsed,prostate,No open trials,Ireland,Leitrim
Ethan Anderson,63,newly_diagnosed,prostate,No open trials,Ireland,Kilkenny
Hannah Smith,64,relapsed,prostate,No open trials,Ireland,Kilkenny
Hannah Lee,66,relapsed,prostate,No open trials,Ireland,Limerick
Hannah Lee,66,relapsed,prostate,No open trials,Lithuania,
Ethan Clark,61,relapsed,prostate,No open trials,Slovenia,
George Clark,59,newly_diagnosed,prostate,No open trials,Belgium,
Fiona Lee,62,relapsed,prostate,No open trials,Malta,
Alice Anderson,64,relapsed,prostate,No open trials,Austria,
Charlie Smith,64,newly_diagnosed,prostate,No open trials,Cyprus,
Diana Johnson,68,relapsed,prostate,No open trials,Sweden,
George Clark,61,newly_diagnosed,prostate,No open trials,Slovenia,
Ethan Clark,67,newly_diagnosed,prostate,No open trials,Greece,
Alice Brown,62,relapsed,prostate,No open trials,Finland,
Hannah Lee,75,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Mayo
Bob Lee,72,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Wexford
George Clark,73,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Louth
Ethan Brown,75,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Louth
Bob Johnson,78,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Louth
Bob Clark,70,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kerry
Charlie Brown,77,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Roscommon
Bob Smith,72,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Carlow
Charlie Anderson,76,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Meath
Charlie Martin,77,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Wicklow
Ethan Lee,74,newly_diagnosed,breast,No open trials,Belgium,
George Smith,75,relapsed,breast,No open trials,Estonia,
Hannah Clark,78,newly_diagnosed,breast,No open trials,Netherlands,
Hannah Johnson,75,newly_diagnosed,breast,No open trials,Czech Republic,
Alice Taylor,71,relapsed,breast,No open trials,Czech Republic,
Alice Johnson,74,newly_diagnosed,breast,No open trials,Luxembourg,
Diana Clark,71,relapsed,breast,No open trials,Estonia,
Bob Martin,73,newly_diagnosed,breast,No open trials,Italy,
Bob Johnson,77,newly_diagnosed,breast,No open trials,Slovenia,
Charlie Lee,76,newly_diagnosed,breast,No open trials,Slovakia,
Diana Clark,75,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Monaghan
Hannah Johnson,70,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Dublin
Alice Anderson,75,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Mayo
Fiona Taylor,69,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Waterford
Diana Clark,77,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Westmeath
Fiona Clark,76,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Waterford
Diana Smith,78,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Monaghan
Bob Lee,77,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Offaly
Charlie Martin,77,relapsed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Limerick
Alice Smith,69,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
George Clark,71,newly_diagnosed,lung,No open trials,Malta,
Diana Taylor,77,newly_diagnosed,lung,No open trials,Hungary,
George Smith,70,relapsed,lung,No open trials,Portugal,
Alice Johnson,78,relapsed,lung,No open trials,Malta,
Ethan Taylor,70,relapsed,lung,No open trials,Hungary,
Fiona Martin,69,newly_diagnosed,lung,No open trials,Spain,
George Smith,76,relapsed,lung,No open trials,Slovakia,
Alice Lee,74,relapsed,lung,No open trials,Lithuania,
Diana Smith,74,newly_diagnosed,lung,No open trials,Poland,
Bob Brown,77,relapsed,lung,No open trials,Hungary,
Bob Brown,69,newly_diagnosed,CLL,No open trials,Ireland,Kerry
Diana Anderson,71,newly_diagnosed,CLL,No open trials,Ireland,Meath
George Clark,77,newly_diagnosed,CLL,No open trials,Ireland,Longford
Ethan Lee,77,newly_diagnosed,CLL,No open trials,Ireland,Louth
Bob Brown,70,newly_diagnosed,CLL,No open trials,Ireland,Limerick
Diana Smith,70,relapsed,CLL,No open trials,Ireland,Roscommon
Hannah Clark,78,newly_diagnosed,CLL,No open trials,Ireland,Laois
Charlie Anderson,70,newly_diagnosed,CLL,No open trials,Ireland,Cavan
Bob Martin,72,newly_diagnosed,CLL,No open trials,Ireland,Laois
Hannah Smith,78,newly_diagnosed,CLL,No open trials,Ireland,Roscommon
Alice Clark,73,newly_diagnosed,CLL,No open trials,Austria,
George Anderson,75,newly_diagnosed,CLL,No open trials,Finland,
Alice Smith,77,newly_diagnosed,CLL,No open trials,Belgium,
George Martin,69,relapsed,CLL,No open trials,Italy,
Hannah Taylor,71,newly_diagnosed,CLL,No open trials,Slovakia,
George Martin,77,relapsed,CLL,No open trials,Czech Republic,
Ethan Clark,71,newly_diagnosed,CLL,No open trials,Germany,
Bob Clark,71,newly_diagnosed,CLL,No open trials,Bulgaria,
Ethan Smith,71,newly_diagnosed,CLL,No open trials,Italy,
Alice Brown,76,relapsed,CLL,No open trials,Belgium,
George Brown,72,newly_diagnosed,myeloma,No open trials,Ireland,Leitrim
Ethan Brown,76,relapsed,myeloma,No open trials,Ireland,Cork
Diana Taylor,75,newly_diagnosed,myeloma,No open trials,Ireland,Kerry
Ethan Taylor,73,relapsed,myeloma,No open trials,Ireland,Wexford
George Clark,75,newly_diagnosed,myeloma,No open trials,Ireland,Kerry
Diana Lee,69,newly_diagnosed,myeloma,No open trials,Ireland,Monaghan
George Clark,69,newly_diagnosed,myeloma,No open trials,Ireland,Roscommon
Alice Smith,78,relapsed,myeloma,No open trials,Ireland,Meath
Alice Taylor,72,relapsed,myeloma,No open trials,Ireland,Waterford
Alice Smith,70,relapsed,myeloma,No open trials,Ireland,Longford
Charlie Smith,74,relapsed,myeloma,No open trials,Italy,
Alice Taylor,77,newly_diagnosed,myeloma,No open trials,Austria,
Ethan Brown,74,relapsed,myeloma,No open trials,Italy,
Bob Johnson,72,relapsed,myeloma,No open trials,Bulgaria,
Ethan Anderson,72,relapsed,myeloma,No open trials,Lithuania,
Bob Anderson,77,relapsed,myeloma,No open trials,Lithuania,
Diana Brown,78,newly_diagnosed,myeloma,No open trials,Cyprus,
Fiona Smith,75,newly_diagnosed,myeloma,No open trials,Estonia,
Bob Johnson,71,newly_diagnosed,myeloma,No open trials,Estonia,
Hannah Anderson,74,relapsed,myeloma,No open trials,Croatia,
Ethan Smith,74,newly_diagnosed,prostate,No open trials,Ireland,Westmeath
Hannah Smith,77,relapsed,prostate,No open trials,Ireland,Mayo
Ethan Johnson,75,newly_diagnosed,prostate,No open trials,Ireland,Dublin
Fiona Johnson,75,relapsed,prostate,No open trials,Ireland,Kildare
Hannah Smith,74,newly_diagnosed,prostate,No open trials,Ireland,Louth
Bob Clark,78,relapsed,prostate,No open trials,Ireland,Leitrim
Diana Martin,69,relapsed,prostate,No open trials,Ireland,Galway
George Taylor,76,newly_diagnosed,prostate,No open trials,Ireland,Kerry
Charlie Taylor,74,relapsed,prostate,No open trials,Ireland,Carlow
Diana Clark,74,relapsed,prostate,No open trials,Ireland,Sligo
Fiona Johnson,72,relapsed,prostate,No open trials,Finland,
Diana Martin,78,relapsed,prostate,No open trials,Netherlands,
George Clark,74,newly_diagnosed,prostate,No open trials,Malta,
Hannah Smith,75,newly_diagnosed,prostate,No open trials,Netherlands,
Diana Martin,72,newly_diagnosed,prostate,No open trials,Italy,
George Martin,75,relapsed,prostate,No open trials,Finland,
Hannah Johnson,70,relapsed,prostate,No open trials,Luxembourg,
Diana Johnson,77,newly_diagnosed,prostate,No open trials,Denmark,
Bob Clark,76,relapsed,prostate,No open trials,Poland,
Diana Lee,77,relapsed,prostate,No open trials,Hungary,
Charlie Taylor,86,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Leitrim
Hannah Anderson,85,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Carlow
Alice Smith,85,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Leitrim
Bob Smith,79,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kildare
Fiona Clark,82,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Donegal
Diana Smith,80,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Cork
Diana Anderson,85,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Wexford
Charlie Johnson,90,relapsed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Kilkenny
Charlie Martin,89,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Sligo
Alice Smith,80,newly_diagnosed,breast,ASCENT-05; CADY Sub-Study; CAMBRIA-2; DESTINY-Breast15; EMBER-4; EPIK-B5; Exosomes in TNBC; EXPERT; MK-2870-012; PREcoopERA; PRIMROSE CSF; Proteomics / Molecular Breast; Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA); TREAT ctDNA study; UCARE; Wavelia,Ireland,Cavan
Diana Taylor,88,relapsed,breast,No open trials,Latvia,
Charlie Smith,83,newly_diagnosed,breast,No open trials,Hungary,
Hannah Clark,86,newly_diagnosed,breast,No open trials,Slovenia,
George Martin,88,newly_diagnosed,breast,No open trials,Denmark,
George Martin,85,newly_diagnosed,breast,No open trials,France,
Alice Anderson,87,relapsed,breast,No open trials,France,
Ethan Johnson,90,newly_diagnosed,breast,No open trials,Luxembourg,
Diana Lee,85,newly_diagnosed,breast,No open trials,Czech Republic,
George Anderson,90,relapsed,breast,No open trials,Malta,
Bob Johnson,82,relapsed,breast,No open trials,Poland,
George Lee,89,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Tipperary
Diana Clark,84,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Clare
Fiona Clark,84,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Mayo
Fiona Smith,84,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Longford
Fiona Brown,83,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Kildare
Ethan Smith,81,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Dublin
Diana Lee,79,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Donegal
Charlie Anderson,86,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Dublin
Diana Anderson,90,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Louth
Diana Lee,85,newly_diagnosed,lung,BRAND; DeLLphi-305; HARMONi-3; Krystal-7; SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours; V940-002,Ireland,Donegal
Fiona Brown,86,relapsed,lung,No open trials,Poland,
Hannah Clark,87,relapsed,lung,No open trials,Greece,
George Johnson,83,relapsed,lung,No open trials,Sweden,
Charlie Johnson,89,newly_diagnosed,lung,No open trials,Belgium,
Fiona Lee,87,relapsed,lung,No open trials,Bulgaria,
Charlie Brown,88,relapsed,lung,No open trials,Portugal,
Alice Lee,90,relapsed,lung,No open trials,Cyprus,
Hannah Lee,85,relapsed,lung,No open trials,Estonia,
Alice Taylor,85,newly_diagnosed,lung,No open trials,Luxembourg,
Diana Martin,86,relapsed,lung,No open trials,Czech Republic,
Alice Lee,81,relapsed,CLL,No open trials,Ireland,Donegal
George Johnson,82,newly_diagnosed,CLL,No open trials,Ireland,Mayo
Bob Clark,79,relapsed,CLL,No open trials,Ireland,Kilkenny
Fiona Martin,81,newly_diagnosed,CLL,No open trials,Ireland,Cork
Ethan Anderson,86,relapsed,CLL,No open trials,Ireland,Waterford
Ethan Johnson,88,relapsed,CLL,No open trials,Ireland,Offaly
George Taylor,86,relapsed,CLL,No open trials,Ireland,Clare
Diana Taylor,83,newly_diagnosed,CLL,No open trials,Ireland,Carlow
Bob Clark,82,relapsed,CLL,No open trials,Ireland,Kilkenny
Diana Johnson,82,newly_diagnosed,CLL,No open trials,Ireland,Limerick
Diana Smith,84,newly_diagnosed,CLL,No open trials,Lithuania,
Ethan Smith,81,newly_diagnosed,CLL,No open trials,Bulgaria,
George Johnson,84,relapsed,CLL,No open trials,Latvia,
George Martin,79,newly_diagnosed,CLL,No open trials,Poland,
Fiona Smith,89,relapsed,CLL,No open trials,France,
Charlie Brown,84,relapsed,CLL,No open trials,Hungary,
George Lee,83,newly_diagnosed,CLL,No open trials,Netherlands,
Diana Johnson,88,relapsed,CLL,No open trials,Luxembourg,
Bob Taylor,79,relapsed,CLL,No open trials,Bulgaria,
Alice Martin,86,newly_diagnosed,CLL,No open trials,France,
Diana Martin,86,relapsed,myeloma,No open trials,Ireland,Meath
Charlie Lee,85,newly_diagnosed,myeloma,No open trials,Ireland,Westmeath
Charlie Johnson,80,newly_diagnosed,myeloma,No open trials,Ireland,Monaghan
George Anderson,82,newly_diagnosed,myeloma,No open trials,Ireland,Wicklow
Fiona Clark,90,newly_diagnosed,myeloma,No open trials,Ireland,Leitrim
Ethan Johnson,87,relapsed,myeloma,No open trials,Ireland,Westmeath
Fiona Clark,86,newly_diagnosed,myeloma,No open trials,Ireland,Limerick
Fiona Clark,86,newly_diagnosed,myeloma,No open trials,Ireland,Meath
Charlie Martin,79,relapsed,myeloma,No open trials,Ireland,Leitrim
George Smith,90,newly_diagnosed,myeloma,No open trials,Ireland,Clare
Alice Smith,90,newly_diagnosed,myeloma,No open trials,Romania,
Bob Anderson,88,relapsed,myeloma,No open trials,Italy,
Ethan Johnson,82,newly_diagnosed,myeloma,No open trials,Denmark,
Charlie Anderson,84,relapsed,myeloma,No open trials,Bulgaria,
Charlie Lee,85,newly_diagnosed,myeloma,No open trials,Austria,
Fiona Martin,81,relapsed,myeloma,No open trials,Hungary,
Diana Brown,88,newly_diagnosed,myeloma,No open trials,Latvia,
Bob Anderson,84,newly_diagnosed,myeloma,No open trials,Estonia,
Alice Johnson,79,newly_diagnosed,myeloma,No open trials,Slovakia,
Charlie Lee,81,relapsed,myeloma,No open trials,Latvia,
Ethan Lee,88,relapsed,prostate,No open trials,Ireland,Kerry
Charlie Martin,88,relapsed,prostate,No open trials,Ireland,Offaly
Bob Johnson,88,relapsed,prostate,No open trials,Ireland,Carlow
Ethan Martin,83,relapsed,prostate,No open trials,Ireland,Louth
Fiona Anderson,79,relapsed,prostate,No open trials,Ireland,Kerry
Ethan Anderson,87,newly_diagnosed,prostate,No open trials,Ireland,Longford
Diana Anderson,82,relapsed,prostate,No open trials,Ireland,Waterford
Fiona Brown,88,newly_diagnosed,prostate,No open trials,Ireland,Dublin
Charlie Martin,80,relapsed,prostate,No open trials,Ireland,Limerick
Ethan Brown,89,newly_diagnosed,prostate,No open trials,Ireland,Westmeath
Alice Smith,89,newly_diagnosed,prostate,No open trials,Austria,
Hannah Martin,86,newly_diagnosed,prostate,No open trials,Poland,
Diana Clark,89,newly_diagnosed,prostate,No open trials,Slovenia,
Fiona Smith,84,relapsed,prostate,No open trials,Luxembourg,
Bob Taylor,84,newly_diagnosed,prostate,No open trials,Slovakia,
Ethan Lee,90,relapsed,prostate,No open trials,Estonia,
Hannah Anderson,84,newly_diagnosed,prostate,No open trials,Slovakia,
George Martin,79,relapsed,prostate,No open trials,Netherlands,
Bob Smith,79,relapsed,prostate,No open trials,Poland,
Charlie Martin,82,relapsed,prostate,No open trials,Italy,
